Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...
Cancer
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...
Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...
AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...
CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...
Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...
Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System
RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...